Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

Vanda Pharmaceuticals Announces Positive Phase III Results for HETLIOZ®(tasimelteon) in ...

30 September 2026 · By · Wire by Fusion42

Published

30 September 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at prnewswire.com →

◆ Verified

Fusion42 · 30 September 2026 · Fusion42 review

Vanda Pharmaceuticals announced positive Phase III trial results for HETLIOZ® (tasimelteon) in treating Delayed Sleep-Wake Phase Disorder (DSWPD), showing a statistically significant earlier sleep onset compared to placebo. The company plans to submit a supplemental New Drug Application to the FDA for approval of HETLIOZ® as the first treatment for DSWPD.

This Wire brief sits within Fusion42's coverage of Biotech.

◆ ◆ The Wire takeaway

You can open a treatment-focused product line in sleep disorders as the first FDA-approved drug for DSWPD nears approval. The shift creates a regulatory green light for solutions addressing complex circadian rhythm issues.

◆ Coverage

1 source · 30 Sep 2026

◆ Related on Wire

◆ Topics

Biotechphase-iiisleep-disorderfda-approvalclinical-trialbiopharma